A. Salud

A. Carrato, A. Abad, C. Montagut, 2021, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

Should a cytologic study be ordered in transudative pleural effusions?

J. M. Porcel, M. Vives, A. Salud, 1999, Chest.

Rapid pleurodesis with doxycycline through a small-bore catheter for the treatment of metastatic malignant effusions

J. M. Porcel, M. Nabal, A. Esquerda, 2006, Supportive Care in Cancer.

Soluble oncoprotein 185HER-2 in pleural fluid has limited usefulness for the diagnostic evaluation of malignant effusions.

J. M. Porcel, A. Esquerda, M. Vives, 2005, Clinical biochemistry.

Accuracy of fluorodeoxyglucose-PET imaging for differentiating benign from malignant pleural effusions: a meta-analysis.

J. M. Porcel, S. Bielsa, M. Martinez-Alonso, 2015, Chest.

Genomic Profiling of HER2-Positive Gastric Cancer: PI3K/Akt/mTOR Pathway as Predictor of Outcomes in HER2-Positive Advanced Gastric Cancer Treated with Trastuzumab.

F. López-Ríos, L. Paz-Ares, M. Alsina, 2018, The oncologist.

Clinical Impact of Presurgery Circulating Tumor DNA after Total Neoadjuvant Treatment in Locally Advanced Rectal Cancer: A Biomarker Study from the GEMCAD 1402 Trial

B. Bellosillo, C. Montagut, J. Maurel, 2021, Clinical Cancer Research.

Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial.

R. Jain, C. Montagut, J. Maurel, 2019, JAMA oncology.

Prognostic significance of DNA ploidy, S‐phase fraction, and P‐glycoprotein expression in colorectal cancer

J. M. Porcel, R. Camplejohn, B. Raikundalia, 1999, Journal of surgical oncology.

TTF‐1 and napsin A on cell blocks and supernatants of pleural fluids for labeling malignant effusions

J. M. Porcel, S. Bielsa, X. Matías-Guiu, 2015, Respirology.

Effect of aflibercept plus FOLFIRI and potential efficacy biomarkers in patients with metastatic colorectal cancer: the POLAF trial

J. Tabernero, E. Polo, M. Valladares-Ayerbes, 2021, British Journal of Cancer.

Clinical Impact of Circulating Tumor RAS and BRAF Mutation Dynamics in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy Plus Anti-Epidermal Growth Factor Receptor Therapy.

F. Rojo, B. Bellosillo, C. Montagut, 2019, JCO precision oncology.

Preoperative chemoradiation with oxaliplatin and 5-fluorouracil in locally advanced rectal carcinoma.

A. Tres, J. Lambea, A. Antón, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Three-year outcomes of GCR-3: A phase II randomized trial comparing conventional preoperative chemoradiation (CRT) followed by surgery and postoperative adjuvant chemotherapy (CT) with induction CT followed by CRT and surgery in locally advanced rectal cancer.

J. Aparicio, C. Pericay, R. Vera, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

PULSE, a phase 2 study of mFOLFOX6-panitumumab (P) with biomarker stratification as first-line chemotherapy (CT), in patients (pts) with KRAS (exon 2) metastatic colorectal cancer (mCRC). A GEMCAD 09-03 study

M. Rubini, J. Aparicio, J. Feliu, 2016 .

Prospective evaluation of BRAF, PI3K and PTEN as predictive and prognostic biomarkers in first-line advanced KRAS wild-type colorectal cancer treated with FOLFOX or FOLFIRI plus bi-weekly cetuximab. GEMCAD 10-02

F. Rojo, J. Feliu, M. Cuatrecasas, 2016 .

Randomized phase II trial of modified (m) FOLFOX6 induction chemotherapy with or without aflibercept before standard chemoradiotherapy (CRT) and total mesorectal excision (TME) in patients with high-risk rectal adenocarcinoma (HRRC): Final results of the GEMCAD 1402, and by molecular subtypes.

L. Vermeulen, C. Montagut, J. Maurel, 2020 .

RIA: Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial.

M. Martín, C. Pericay, R. García-Carbonero, 2018 .

Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer

C. García-Girón, J. Feliu, R. López, 2010, British Journal of Cancer.

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial.

C. Montagut, C. Pericay, G. Brown, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

XELOX (capecitabine and oxaliplatin) as 1st line treatment for elderly patients (pts) with advanced/metastatic colorectal cancer (MCRC).

J. Feliu, M. González-Barón, P. Escudero, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Predictors of Indwelling Pleural Catheter Removal and Infection

J. M. Porcel, S. Bielsa, A. Salud, 2019, Journal of bronchology & interventional pulmonology.

Radiologic and pathologic prognostic factors after neoadyuvant chemotherapy for T3 rectal cancer (RC): 3-year update GEMCAD 0801-trial.

C. Montagut, J. Aparicio, J. Feliu, 2015 .

Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

J. Aparicio, M. Valladares-Ayerbes, M. Salgado, 2022, Cancers.

Microenvironmental Reactive Oxygen Species in Colorectal Cancer: Involved Processes and Therapeutic Opportunities

A. Sorolla, E. Parisi, M. A. Sorolla, 2021, Cancers.

A Review of Clinical Studies and Practical Guide for the Administration of Triplet Chemotherapy Regimens with Bevacizumab in First-line Metastatic Colorectal Cancer

M. Ychou, A. Stein, F. Loupakis, 2015, Targeted Oncology.

Level of HER2 gene amplification predicts response and overall survival in HER2-positive advanced gastric cancer treated with trastuzumab.

M. Hidalgo, F. López-Ríos, F. Rojo, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic Factors Involved in the Epithelial–Mesenchymal Transition Process in Colorectal Cancer Have a Preponderant Role in Oxidative Stress: A Systematic Review and Meta-Analysis

A. Sorolla, E. Parisi, M. A. Sorolla, 2020, Cancers.

Correlation of Hypertension and Proteinuria with Outcome in Elderly Bevacizumab-Treated Patients with Metastatic Colorectal Cancer

C. García-Girón, J. Aparicio, J. Feliu, 2015, PloS one.

Are Transcription Factors Plausible Oncotargets for Triple Negative Breast Cancers?

A. Sorolla, E. Parisi, S. Morales, 2022, Cancers.

Interferon and disseminated Langerhans cell histiocytosis.

J. Albanell, J. Bellmunt, T. Español, 1992, Medical and pediatric oncology.

Diving into the Pleural Fluid: Liquid Biopsy for Metastatic Malignant Pleural Effusions

A. Sorolla, E. Parisi, M. A. Sorolla, 2021, Cancers.

Endobronchial Metastases in Colorectal Adenocarcinoma

A. Salud, P. Vicente, J. Bellmunt, 1992, Tumori.

[Treatment with interferon of systemic Langerhans-cell histiocytosis in an adult].

J. Albanell, J. Bellmunt, T. Español, 1990, Medicina clinica.

Endobronchial metastatic disease: Analysis of 32 cases

J. Bellmunt, A. Rovirosa, A. Salud, 1996 .

Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trial†.

C. Montagut, J. Aparicio, J. Maurel, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer d

S. Polo, J. Aparicio, J. Maurel, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A critical review of HER2-positive gastric cancer evaluation and treatment: from trastuzumab, and beyond.

F. López-Ríos, F. Lordick, J. Aparicio, 2014, Cancer letters.

Randomised study of tegafur and oral leucovorin versus intravenous 5-fluorouracil and leucovorin in patients with advanced colorectal cancer.

Á. Arcusa, L. Cirera, P. Escudero, 2005, European journal of cancer.

Gemcitabine-erlotinib versus gemcitabine-erlotinib-capecitabine in the first-line treatment of patients with metastatic pancreatic cancer: Efficacy and safety results of a phase IIb randomised study from the Spanish TTD Collaborative Group.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.

Clinical guideline SEOM: hepatocellular carcinoma

J. García-Foncillas, J. Feliu, M. Salgado, 2015, Clinical and Translational Oncology.

Endobronchial metastatic disease: analysis of 32 cases

J. Bellmunt, A. Rovirosa, A. Salud, 1997 .

Clinical Impact of 18F-FDG-PET in the Suspicion of Recurrent Ovarian Carcinoma Based on Elevated Tumor Marker Serum Levels.

J. Jiménez-Bonilla, A. Salud, A. Maldonado, 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

Recommendations and expert opinion on the adjuvant treatment of colon cancer in Spain

J. Aparicio, J. Feliu, M. Valladares-Ayerbes, 2011, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Breakthrough cancer pain: review and calls to action to improve its management

C. Camps Herrero, A. Salud, Y. Escobar Álvarez, 2020, Clinical and Translational Oncology.

High levels of tumor markers in pleural fluid correlate with poor survival in patients with adenocarcinomatous or squamous malignant effusions.

S. Bielsa, E. Arellano, A. Esquerda, 2009, European journal of internal medicine.

MRI assessment and outcomes in patients receiving neoadjuvant chemotherapy only for primary rectal cancer: long-term results from the GEMCAD 0801 trial

C. Montagut, C. Pericay, G. Brown, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial.

C. Montagut, J. Aparicio, M. Martín, 2014, The oncologist.

XELOX (capecitabine plus oxaliplatin) as first-line treatment for elderly patients over 70 years of age with advanced colorectal cancer

J. Feliu, E. Casado, M. González-Barón, 2006, British Journal of Cancer.

Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study)

M. Salgado, V. Alonso, M. Méndez, 2014, BMC Cancer.

Orbital metastases from transitional-cell cancer of the urinary bladder.

E. Felip, J. Bellmunt, J. Giralt, 1991, Urologia internationalis.

[Unilateral exophthalmos secondary to orbital metastasis as initial manifestation of breast cancer].

A. Balil, A. Salud, J. Porcel, 2002, Anales de medicina interna.

A Novel Immunohistochemical Signature with the Quantification of HER2 Predicts the Complete Response in HER2-Positive Breast Cancer

S. Bielsa, M. A. Sorolla, A. Salud, 2019 .

Prognostic value of c-FLIPL/s, HIF-1α, and NF-κβ in stage II and III rectal cancer

X. Matías-Guiu, M. Martinez-Alonso, A. Salud, 2014, Virchows Archiv.

Prevalence, clinical characteristics, and outcome of pleural effusions in ovarian cancer

S. Bielsa, P. Murata, A. Salud, 2021, Pleura and peritoneum.

Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial

J. Aparicio, J. Feliu, E. Casado, 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[Ovarian cancer in a female patient with von Recklinghausen's disease].

E. Felip, J. D. Del Campo, A. Salud, 1991, Medicina clínica (Ed. impresa).

Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients.

J. Porta, A. Salud, J. A. Schoenenberger, 1998, Journal of Pain and Symptom Management.

Cell-free DNA Concentration and Pattern Fragmentation in Pleural Fluid and Plasma to Detect Malignant Effusions.

S. Bielsa, A. Sorolla, E. Parisi, 2021, Annals of the American Thoracic Society.

Endobronchial metastatic disease: Analysis of 32 cases

J. Bellmunt, A. Rovirosa, A. Salud, 1996, Journal of surgical oncology.

Cetuximab Given Every 2 Weeks plus Irinotecan Is an Active and Safe Option for Previously Treated Patients with Metastatic Colorectal Cancer

Cristina Martín, C. Pericay, C. Grande, 2010, Chemotherapy.

First-line single-agent regorafenib in frail patients with metastatic colorectal cancer: a pilot phase II study of the Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)

A. Carrato, E. Polo, E. Grande, 2019, BMC Cancer.

M. Martín, F. Rivera, R. Pazo-Cid, 2017, European journal of cancer.